Article
A pharmacogenetic pilot study reveals MTHFR, DRD3, and MDR1 polymorphisms as biomarker candidates for slow atorvastatin metabolizers.
BMC cancer - 8 Feb 2016
León-Cachón Rafael B R, Ascacio-Martínez Jorge A, Gamino-Peña María E, Cerda-Flores Ricardo M, Meester Irene, Gallardo-Blanco Hugo L, Gómez-Silva Magdalena, Piñeyro-Garza Everardo, Barrera-Saldaña Hugo A
Abstract excerpt
BACKGROUND: The genetic variation underlying atorvastatin (ATV) pharmacokinetics was evaluated in a Mexican population. Aims of this study were: 1) to reveal the frequency of 87 polymorphisms in 36 genes related to drug metabolism in healthy Mexican volunteers, 2) to evaluate the impact of these polymorphisms on ATV pharmacokinetics, 3) to classify the ATV metabolic phenotypes of healthy volunteers, and 4) to...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.